30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

2Q14 Revenue: Anika Therapeutics

Orthobiologic sales $18.2MM, +11% (ex-U.S. MONOVISC +27%)

  • Received $5MM milestone payment associated with U.S. MONOVISC license agreement
  • Majority of U.S. sales reflect physician/patient conversion from competing single-injection products to MONOVISC
  • Expecting to have new J-code from CMS for MONOVISC reimbursement effective 1Q15
  • No evidence of U.S. ORTHOVISC cannibalization yet; pursuing goal of MONOVISC at 5% U.S. market share within initial 12 months
  • Established new distribution agreements in Iraq, Jordan, South Africa, Sweden
  • Seeks to expand viscosupplementation distribution into Asia, Latin America, Middle East, leading with MONOVISC
  • Pursuing late 2015/early 2016 launch of new products: Cingal HA+steroid single-injection and new “value-oriented” viscosupplement (latter ex-U.S.)
  • Hoping to use Europe clinical trial data (~360 patients) to support U.S. regulatory clearance of Cingal